VulnCheck Raises $7.95M in Seed Funding
VulnCheck, a Lexington, MA-based exploit intelligence company, closed its seed funding round at a total of $7.95m, with $4.75m in new funding.
VulnCheck, a Lexington, MA-based exploit intelligence company, closed its seed funding round at a total of $7.95m, with $4.75m in new funding.
Langdock, a Berlin, Germany-based provider of a platform empowering companies to leverage large language models (LLMs) while staying in control of their data, raised $3M in Seed funding.
Volo Sports, a Baltimore, MD-based provider of community-focused, tech-enabled adult social sports and curated events, received a strategic growth investment from Manhattan West.
Softloans, a Vilnius, Lithuania-based fintech startup, raised €1M in Pre-Seed funding.
Anvilogic, a Palo Alto, CA-based provider of a multi-data platform SIEM, raised $45M in Series C funding.
Xfactor.io, a San Francisco, CA-based provider of a comprehensive AI-powered revenue platform, raised $16M in Series A funding.
Condoit, a Birmingham, AL-based provider of a platform for digitizing the electrical industry, raised $4.5M in Seed funding.
Cape, an Arlington, VA-based privacy-first mobile carrier, raised $61M in funding.
Centrifuge, an onchain finance startup, raised $15m in Series A funding.
UniUni, a Richmond, BC, Canada-based company which specializes in e-commerce last-mile logistics, raised US$50M in Series C funding.
Avive Solutions, a San Francisco, CA-based developer of a connected automated external defibrillator (AED) – the Avive Connect AEDⓇ, raised $56.5M in Growth Equity funding.
Pathios Therapeutics, an Oxford, UK-based biotech company focused on the development of therapies for cancer, raised $25M in first closed of Series B funding.
Nava Health, a Columbia, MD-based group of holistic health and treatment centers focused on integrative medicine, raised an undisclosed amount in revenue-based funding from Decathlon Capital.
Hatch, a NYC-based provider of AI-powered donor engagement solutions for nonprofits, raised $3M in Seed funding.
Neurenati Therapeutics, a Montreal, Québec, Canada-based biotech company dedicated to developing therapies for rare diseases, raised $1.38M in funding.